Evolution of GMO requirements for innovative investigational medicinal products upon transition to the EU CTR


The EU CTR replaced the EU CTD on 31 January 2022, which impacts investigational medicinal products that fall under genetically modified organisms (GMO-IMPs). This article discusses the specificities of the new CTR process for GMO-IMPs and updates on the GMO application processes in light of these changes.

 This is member-only content

To read this article, SIGN IN NOW if you are a TOPRA member.

Not a TOPRA member yet? 

Join now to get access to:

  • Features and specialist articles
  • CPD supplements
  • Comprehensive archive

Not sure yet?  Read one of our free editorials to see what you’re missing out on!